Nebido

ApprovedSmall molecule

Bayer

Nebido is one of 77 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

HypogonadismActive, not recruiting

Metabolic SyndromePhase 3

Active, not recruiting

HypogonadismApproved

Active, not recruiting

Competition

Competitive Landscape

190 competitors in Metabolic Syndrome

#DrugCompanyPhaseTrials

Precose

Bayer

Phase 3

1 2

Glucophage

Boehringer Ingelheim

Phase 3

1 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

1 5

Kineret

SSwedish Orphan Biovitrum

Phase 3

1 6

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 7

Topamax

WWim Janssens

Phase 3

1 8

Comparator: Statins

Merck & Co.

Phase 3

1 9

Rimonabant

Sanofi

Phase 3

—10

Pioglitazone and Insulin

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metabolic Syndrome1 trial

The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men

Unknown status·RRussian Academy of Medical Sciences·Phase 3·NCT00696748·250 enrolled

Testosterone1 trial

Older Men and Testosterone

Completed·UUniversity Hospital of North Norway·N/A·NCT00119483·200 enrolled

Treatment1 trial

Pubertal Replacement In Boys Study Nebido and Testoviron Depot Treatment

Completed·NNU-Hospital Organization, Sweden·N/A·NCT05417035·27 enrolled

Chronic Stable Angina1 trial

Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT00131183·15 enrolled

Hypogonadism1 trial

Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks

Withdrawn· Bayer logo

Bayer·Phase 4·NCT00710827

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Nebido. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nebido compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nebido. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Nebido

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metabolic Syndrome1 trial

Testosterone1 trial

Treatment1 trial

Chronic Stable Angina1 trial

Hypogonadism1 trial

References

Drug Info

Quick Facts

Related News